Families who believe their loved ones contracted covid-19 while hospitalized are finding they have little recourse following a wave of liability shield legislation pushed by business interests.
A KHN investigation finds that hospitals with high rates of covid patients who didn’t have the diagnosis when they were admitted have rarely been held accountable due to multiple gaps in government oversight.
About 21% of patients in the U.S. diagnosed with covid during a hospital stay died, according to data analyzed for KHN. In-hospital rates of spread varied widely in California and across the country — and patients had no way of checking them.
En promedio, alrededor del 1,7% de los pacientes con covid internados en hospitales de los Estados Unidos fueron diagnosticados con el virus en estas instalaciones, según un análisis de los registros de Medicare del 1 de abril al 30 de septiembre de 2020.
The House oversight committee is requesting conflict-of-interest disclosure forms from a National Academies committee studying organ transplants. KHN previously reported on apparent conflicts among members of a committee studying drug waste.
Congress tapped a national academies committee to examine a drug cost issue. It got a report that includes “egregious” failures to disclose conflicts of interest.
Thousands of schools have spent millions of federal covid relief dollars snapping up air cleaning technology that claims to inactivate covid-19. But the devices fall into a regulatory gap.
Citing the deaths of thousands of health care workers, the new rules will force employers to report fatalities or hospitalizations to the Occupational Safety and Health Administration, and provide higher-quality protective gear, among other actions.
As vaccine expiration dates loom, states with hundreds of thousands of doses on hand say demand is tanking and there’s no easy way to donate to other states or countries that might want them
The technology that schools have been snapping up in the fight against covid “has not shown significant disinfection effectiveness” to install on its planes, Boeing found. Now the company’s study is being debated in a proposed class-action suit.